6533b7d7fe1ef96bd1268669
RESEARCH PRODUCT
Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.
Xavier PintóÁNgel DíazMariano BlascoAntonio Hernández-mijaresJuan F. AscasoÁNgel BreaJuan Pedro-botetJesús Millánsubject
medicine.medical_specialtyendocrine system diseaseschemistry.chemical_compoundTriglycerides/HDL CholesterolInternal medicineMedicineHumanscardiovascular diseasesTriglyceridesGeneral Environmental ScienceLipoprotein cholesterolDyslipidemiasbusiness.industryCholesterolCholesterol HDLGeneral Engineeringnutritional and metabolic diseasesAtherosclerosisEuropechemistryPractice Guidelines as TopicCardiologyEuropean atherosclerosis societyGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)businessdescription
In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein cholesterol.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-11-17 | Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis |